5 news items
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
ALNY
2 May 24
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
ALNY
30 Apr 24
interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
ALNY
30 Apr 24
interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
ALNY
7 Apr 24
.
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
ALNY
5 Mar 24
.
About RNAi
RNAi (RNA interference) is a natural cellular
- Prev
- 1
- Next